See more : Hirogin Holdings, Inc. (7337.T) Income Statement Analysis – Financial Results
Complete financial analysis of RenovaCare, Inc. (RCAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RenovaCare, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bank of America Corporation (BAC-PL) Income Statement Analysis – Financial Results
- Vincerx Pharma, Inc. (VINCW) Income Statement Analysis – Financial Results
- Japan Hospice Holdings Inc. (7061.T) Income Statement Analysis – Financial Results
- Interfor Corporation (IFP.TO) Income Statement Analysis – Financial Results
- Aquis Exchange PLC (AQX.L) Income Statement Analysis – Financial Results
RenovaCare, Inc. (RCAR)
About RenovaCare, Inc.
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Scottsdale, Arizona.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.49K | 32.79K | 39.85K | 51.13K | 13.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 919.42K | 463.29K | 153.71K | 0.00 | 66.43K |
| Cost of Revenue | 0.00 | 10.97K | 22.02K | 264.00 | 317.00 | 317.00 | 53.00 | 0.00 | 0.00 | 0.00 | 32.39K | 249.18K | 24.99K | 42.98K | 9.08K | 9.83K | 56.55K | 25.52K | 0.00 | 0.00 | 226.35K | 258.61K | -138.82K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -10.97K | -22.02K | -264.00 | -317.00 | -317.00 | -53.00 | 0.00 | 0.00 | 0.00 | -12.89K | -216.39K | 14.86K | 8.15K | 4.69K | -9.83K | -56.55K | -25.52K | 0.00 | 0.00 | 693.06K | 204.68K | 292.53K | 0.00 | 66.43K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -66.14% | -660.00% | 37.29% | 15.94% | 34.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 75.38% | 44.18% | 190.31% | 0.00% | 100.00% |
| Research & Development | 0.00 | 3.20M | 4.13M | 745.95K | 368.95K | 574.09K | 309.50K | 281.22K | 975.67K | 0.00 | 0.00 | 36.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 2.20M | 5.54M | 2.94M | 1.64M | 2.12M | 1.59M | 1.04M | 1.16M | 628.55K | 248.60K | 536.09K | 0.00 | 312.16K | 0.00 | 7.95K | 47.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.29K | 34.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 2.20M | 5.54M | 2.94M | 1.64M | 2.12M | 1.59M | 1.04M | 1.16M | 628.55K | 248.60K | 536.09K | 215.46K | 312.16K | 190.69K | 27.24K | 81.84K | 56.54K | 133.67K | 579.71K | 845.67K | 558.77K | 967.59K | 747.99K | 355.02K |
| Other Expenses | 0.00 | 931.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.33K | 3.26K | 107.16K | 0.00 | 93.44K | 375.00 | 1.06K | 14.17K | 42.96K | 125.32K | 125.32K | 0.00 | 0.00 | 0.00 | 14.34K |
| Operating Expenses | 0.00 | 5.41M | 9.68M | 3.69M | 2.01M | 2.70M | 1.90M | 1.32M | 2.13M | 628.55K | 261.93K | 576.21K | 322.62K | 312.16K | 284.14K | 27.61K | 82.90K | 70.71K | 176.63K | 705.03K | 970.99K | 558.77K | 967.59K | 747.99K | 369.36K |
| Cost & Expenses | 0.00 | 5.41M | 9.68M | 3.69M | 2.01M | 2.70M | 1.90M | 1.32M | 2.13M | 628.55K | 261.93K | 825.39K | 347.61K | 355.15K | 293.22K | 27.61K | 82.90K | 70.71K | 176.63K | 705.03K | 1.20M | 817.38K | 828.77K | 747.99K | 369.36K |
| Interest Income | 0.00 | 6.42K | 128.76K | 332.24K | 22.45K | 3.14K | 1.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.30K | 2.93K | 1.86K | 2.75K | 1.58K | 5.82K | 16.04K | 36.13K | 86.60K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 135.27K | 996.65K | 180.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 375.00 | 1.06K | 0.00 | 0.00 | 614.00 | 518.00 | 0.00 | 0.00 | 38.33K | 71.06K |
| Depreciation & Amortization | 228.49K | 10.97K | 22.02K | 264.00 | 317.00 | 317.00 | 53.00 | 1.31K | 2.13K | 2.22 | 1.53K | 3.26K | 4.04M | -1.24M | 93.44K | 0.00 | -36.04K | 14.17K | 42.96K | 125.32K | 125.32K | 170.89K | 183.09K | 0.00 | 0.00 |
| EBITDA | 0.00 | -5.40M | -9.53M | -3.36M | -2.01M | -2.70M | -1.90M | -1.32M | -2.13M | -628.55K | -239.38K | -786.07K | 3.65M | -596.92K | -186.00K | -27.61K | -104.23K | -53.80K | -133.67K | -579.71K | -152.61K | -183.21K | -491.98K | -747.99K | -302.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,227.96% | -18,420.46% | 9,163.04% | -3,671.87% | -1,350.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -16.60% | -39.54% | -320.06% | 0.00% | -456.05% |
| Operating Income | 0.00 | -5.41M | -9.68M | -3.69M | -2.01M | -2.70M | -1.90M | -1.32M | -2.13M | -628.55K | -243.96K | -792.60K | -387.01K | -639.91K | -279.45K | -27.61K | -82.90K | -70.71K | -176.63K | -705.03K | -277.93K | -354.09K | -858.15K | -747.99K | -302.93K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | -2,417.42% | -971.25% | -1,251.43% | -2,029.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -30.23% | -76.43% | -558.29% | 0.00% | -456.05% |
| Total Other Income/Expenses | 0.00 | 937.69K | 128.76K | 332.24K | -112.82K | -993.52K | -179.67K | 0.00 | 0.00 | 0.00 | 0.00 | 5.25M | -3.88M | 1.91M | 14.30K | 2.55K | 59.23K | 2.75K | 1.58K | 5.21K | 15.52K | 0.00 | 0.00 | 0.00 | 302.93K |
| Income Before Tax | 0.00 | -4.47M | -9.55M | -3.36M | -2.12M | -3.69M | -2.08M | -1.32M | -2.13M | -628.55K | -243.96K | 4.46M | -4.35M | 1.27M | -372.89K | 0.00 | -46.87K | -67.97K | -175.05K | -699.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | 13,595.58% | -10,906.67% | 2,482.79% | -2,708.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.42K | -128.76K | 160.64K | 22.45K | 3.14K | 15.22K | -1.31K | -2.13K | 404.24K | 1.53K | -5.25M | -79.25K | -335.89K | -107.74K | 24.68K | -1.86K | 0.00 | 0.00 | 0.00 | -15.52K | -36.13K | 96.48K | 709.66K | 231.88K |
| Net Income | 0.00 | -4.47M | -9.42M | -3.36M | -2.12M | -3.69M | -2.08M | -1.32M | -2.13M | -1.03M | -243.96K | 4.46M | -4.27M | 1.27M | -265.15K | -24.68K | -45.00K | -67.97K | -175.05K | -699.82K | -262.40K | -317.97K | -771.55K | -709.66K | -231.88K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | 13,595.58% | -10,707.79% | 2,482.79% | -1,925.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28.54% | -68.63% | -501.95% | 0.00% | -349.08% |
| EPS | 0.00 | -0.05 | -0.11 | -0.04 | -0.03 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | 0.00 | 0.07 | -0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 | -0.07 | -0.03 | -0.01 |
| EPS Diluted | 0.00 | -0.05 | -0.11 | -0.04 | -0.03 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | 0.00 | 0.07 | -0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 | -0.07 | -0.03 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 87.35M | 87.35M | 87.24M | 77.75M | 74.39M | 69.77M | 67.23M | 66.58M | 63.40M | 63.08M | 63.08M | 63.08M | 63.08M | 59.37M | 96.52M | 96.63M | 96.63M | 96.63M | 96.63M | 15.98M | 11.80M | 11.80M | 23.24M | 23.05M |
| Weighted Avg Shares Out (Dil) | 0.00 | 87.35M | 87.35M | 87.24M | 77.75M | 74.39M | 69.77M | 67.23M | 66.58M | 63.40M | 63.08M | 63.08M | 63.08M | 63.08M | 59.37M | 96.52M | 96.63M | 96.63M | 96.63M | 96.63M | 15.98M | 11.80M | 11.80M | 23.24M | 23.05M |
RCAR Investor Notice: Rosen, Nationally Regarded Investor Counsel, Encourages RenovaCare, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - August 24, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive...
RCAR Investor Notice: Rosen, Nationally Regarded Investor Counsel, Encourages RenovaCare, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - August 24, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive...
RenovaCare Class Action Reminder
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RenovaCare To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 22, 2021) - Faruqi & Faruqi, LLP, a leading national securities...
ROSEN, A LEADING LAW FIRM, Encourages RenovaCare, Inc. Investors With Losses Over $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR
New York, New York--(Newsfile Corp. - August 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC Pink: RCAR) between August 14, 2017 and May 28, 2021, inclusive...
RenovaCare Shareholder Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RenovaCare To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 18, 2021) - Faruqi & Faruqi, LLP, a leading national securities...
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of RenovaCare, Inc. (RCAR) Investors
LOS ANGELES, Aug. 18, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired RenovaCare, Inc. ("RenovaCare" or the "Company")...
RCAR BREAKING NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages RenovaCare, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - RCAR
NEW YORK, Aug. 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of RenovaCare, Inc. (OTC: RCAR) between August 14, 2017 and May 28, 2021, inclusive (the "Class Period") of...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in RenovaCare, Inc. of Class Action Lawsuit and Upcoming Deadline - RCAR
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against RenovaCare, Inc. ("RenovaCare" or the "Company") (OTC Pink: RCAR) and certain of its officers. The class action, filed...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against RenovaCare, Inc. (RCAR)
LOS ANGELES, Aug. 16, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 14, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or...
RenovaCare Shareholder Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RenovaCare To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 13, 2021) - Faruqi & Faruqi, LLP, a leading national securities...
Source: https://incomestatements.info
Category: Stock Reports